Objective To investigate the clinical characteristics of children infected with the Omicron variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in Chengdu of China. Methods A retrospective analysis was conducted for the clinical data of 226 children who were infected with the Omicron variant of SARS-Cov-2 and were isolated and treated in Chengdu Shelter Hospital from August 28 to September 21, 2022. According to the presence or absence of clinical symptoms, they were divided into two groups: asymptomatic group and mild symptomatic group. The two groups were compared in terms of clinical characteristics, diagnosis and treatment, and prognosis. Results Among the 226 children infected with the Omicron variant, 71 (31.4%) were asymptomatic and 155 (68.6%) had mild symptoms. Fever and cough were the most common clinical symptoms, with fever in 95 children (61.3%) and cough in 92 children (59.4%). Of all 226 children, 188 (83.2%) received coronavirus disease 2019 (COVID-19) vaccination. The time to nucleic acid clearance ranged from 6 to 26 days, with a nucleic acid clearance rate of 58.0% (131/226). There were no significant differences among different age groups in sex, early symptoms, clinical typing, nucleic acid re-positive rate, nucleic acid clearance rate, and length of hospital stay (P>0.05). There were no significant differences between the asymptomatic and mild symptomatic groups in age, sex, underlying diseases, COVID-19 vaccination, use of Lianhua Qingwen granules, nucleic acid clearance rate, nucleic acid re-positive rate, and length of hospital stay (P>0.05). Conclusions Children infected with the Omicron variant of SARS-Cov-2 in Chengdu generally have mild clinical symptoms, mainly upper respiratory tract infection, which has little threat to the health of children of different ages, and children tend to have a good overall prognosis.
Key words
Severe acute respiratory syndrome coronavirus 2 /
Omicron variant /
Clinical characteristic /
Child
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
References
1 Han P, Li L, Liu S, et al. Receptor binding and complex structures of human ACE2 to spike RBD from Omicron and Delta SARS-CoV-2[J]. Cell, 2022, 185(4): 630-640.e10. PMID: 35093192. PMCID: PMC8733278. DOI: 10.1016/j.cell.2022.01.001.
2 财联社. 世卫组织警告: 世界低估了奥密克戎病毒传播速率前所未见[J]. 高科技与产业化, 2021, 27(12): 9. DOI: 10.28617/n.cnki.nqdrb.2022.001095.
3 王萍, 刘冀珑. 新冠病毒超级突变株: 奥密克戎[J]. 科学, 2022, 74(1): 26-31. DOI: 10.3969/j.issn.0368-6396.2022.01.007.
4 Hui KPY, Ho JCW, Cheung MC, et al. SARS-CoV-2 Omicron variant replication in human bronchus and lung ex vivo[J]. Nature, 2022, 603(7902): 715-720. PMID: 35104836. DOI: 10.1038/s41586-022-04479-6.
5 中国国家卫生健康委员会. 新型冠状病毒肺炎诊疗方案(试行第九版)[J]. 国际流行病学传染病学杂志, 2022, 49(2): 73-80. DOI: 10.3760/cma.j.cn331340-20220325-00065.
6 米元元, 黄海燕, 朱丽群, 等. 新型冠状病毒患者标本采集技术专家共识[J]. 护士进修杂志, 2020, 35(12): 1124-1128. DOI: 10.16821/j.cnki.hsjx.2020.25.016.
7 蒋荣猛, 谢正德, 姜毅, 等. 儿童新型冠状病毒感染诊断、治疗和预防专家共识(第四版)[J]. 中华实用儿科临床杂志, 2022, 37(14): 1053-1065. DOI: 10.3760/cma.j.cn101070-20220610-00698.
8 凌云, 林逸骁, 钱志平, 等. 新型冠状病毒肺炎患者重症化危险因素的临床分析[J]. 中华传染病杂志, 2020, 38(4): 193-198. DOI: 10.3760/cma.j.cn311365-20200211-00055.
9 孙宏源, 张圆, 石存忠, 等. 中西医结合治疗天津地区奥密克戎新型冠状病毒感染患者核酸转阴时间的影响因素分析[J]. 天津中医药, 2022, 39(5): 551-555. DOI: 10.11656/j.issn.1672-1519.2022.05.02.
10 胡纯纯, 许普, 徐柳, 等. Omicron变异株感染的轻型/普通型新型冠状病毒肺炎学龄前儿童出院后短期相关持续症状的随访[J]. 中国当代儿科杂志, 2022, 24(12): 1289-1294. PMID: 36544405. PMCID: PMC9785087. DOI: 10.7499/j.issn.1008-8830.2206034.
11 Hoang A, Chorath K, Moreira A, et al. COVID-19 in 7780 pediatric patients: a systematic review[J]. EClinicalMedicine, 2020, 24: 100433. PMID: 32766542. PMCID: PMC7318942. DOI: 10.1016/j.eclinm.2020.100433.
12 世界卫生组织. 儿童和青少年的COVID-19疾病[EB/OL]. (2021-09-29)[2022-12-09]. https://apps.who.int/iris/bitstream/handle/10665/345575/WHO-2019-nCoV-Sci-Brief-Children-and-adolescents-2021.1-chi.pdf.
13 Syed AM, Ciling A, Taha TY, et al. Omicron mutations enhance infectivity and reduce antibody neutralization of SARS-CoV-2 virus-like particles[J]. Proc Natl Acad Sci U S A, 2022, 119(31): e2200592119. PMID: 35858386. PMCID: PMC9351483. DOI: 10.1073/pnas.2200592119.
14 Wang L, Berger NA, Kaelber DC, et al. Comparison of outcomes from COVID infection in pediatric and adult patients before and after the emergence of Omicron[J]. medRxiv[Preprint]. (2022-01-02) [2022-12-09]. PMID: 35018384. PMCID: PMC8750707. DOI: 10.1101/2021.12.30.21268495.
15 徐言文, 王群, 项琳娟, 等. 儿童新冠病毒Omicron株感染的临床表现与生物学基础[J]. 临床儿科杂志, 2022, 40(10): 795-800. DOI:10.12372/jcp.2022.22e0783.
16 Meng B, Abdullahi A, Ferreira IATM, et al. Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts infectivity and fusogenicity[J]. Nature, 2022, 603(7902): 706-714. PMID: 35104837. PMCID: PMC8942856. DOI: 10.1038/s41586-022-04474-x.
17 陆权. COVID-19全球疫情及其应对策略留给我们的思索[J]. 四川大学学报(医学版), 2021, 52(6): 936-938. PMID: 34841757. DOI:10.12182/20211160103.
18 Noh JY, Jeong HW, Kim JH, et al. T cell-oriented strategies for controlling the COVID-19 pandemic[J]. Nat Rev Immunol, 2021, 21(11): 687-688. PMID: 34497383. PMCID: PMC8424399. DOI: 10.1038/s41577-021-00625-9.
19 Choi SJ, Kim DU, Noh JY, et al. T cell epitopes in SARS-CoV-2 proteins are substantially conserved in the Omicron variant[J]. Cell Mol Immunol, 2022, 19(3): 447-448. PMID: 35043006. PMCID: PMC8764507. DOI: 10.1038/s41423-022-00838-5.
20 Jara A, Undurraga EA, Zubizarreta JR, et al. Effectiveness of CoronaVac in children 3-5 years of age during the SARS-CoV-2 Omicron outbreak in Chile[J]. Nat Med, 2022, 28(7): 1377-1380. PMID: 35605637. PMCID: PMC9307483. DOI: 10.1038/s41591-022-01874-4.
21 Price AM, Olson SM, Newhams MM, et al. BNT162b2 protection against the Omicron variant in children and adolescents[J]. N Engl J Med, 2022, 386(20): 1899-1909. PMID: 35353976. PMCID: PMC9006785. DOI: 10.1056/NEJMoa2202826.
22 Acuti Martellucci C, Flacco ME, Soldato G, et al. Effectiveness of COVID-19 vaccines in the general population of an Italian region before and during the Omicron wave[J]. Vaccines (Basel), 2022, 10(5): 662. PMID: 35632418. PMCID: PMC9146679. DOI: 10.3390/vaccines10050662.
23 Maslo C, Friedland R, Toubkin M, et al. Characteristics and outcomes of hospitalized patients in South Africa during the COVID-19 Omicron wave compared with previous waves[J]. JAMA, 2022, 327(6): 583-584. PMID: 34967859. PMCID: PMC8719272. DOI: 10.1001/jama.2021.24868.
24 Elliott P, Bodinier B, Eales O, et al. Rapid increase in Omicron infections in England during December 2021: REACT-1 study[J]. Science, 2022, 375(6587): 1406-1411. PMID: 35133177. PMCID: PMC8939772. DOI: 10.1126/science.abn8347.
25 张可, 蒋思远, 严恺, 等. 新型冠状病毒Omicron变异株流行期间新生儿感染16例临床特征分析[J]. 中华儿科杂志, 2022, 60(11): 1158-1162. PMID: 36319150. DOI: 10.3760/cma.j.cn112140-20220617-00561.
26 Wang L, Berger NA, Kaelber DC, et al. COVID infection rates, clinical outcomes, and racial/ethnic and gender disparities before and after Omicron emerged in the US[J]. medRxiv[Preprint]. (2022-02-22) [2023-01-15]. PMID: 35233579. PMCID: PMC8887070. DOI: 10.1101/2022.02.21.22271300.
27 张静, 王逸, 樊巍, 等. 为何奥密克戎让儿童成重灾区[N]. 环球时报, 2022-04-25(007). DOI: 10.28378/n.cnki.nhqsb.2022.003566.
28 焦富勇, 马蕾. 加强儿童奥密克戎感染的防治[J]. 中国当代儿科杂志, 2022, 24(4): 345-349. PMID: 35527405. PMCID: PMC9044981. DOI: 10.7499/j.issn.1008-8830.2201001.
PDF(561 KB)
